Ordenar

Buscar

01/11/2025 Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study
Puente, A, Turón, F, Martínez, J, Fortea, JI, Guerra, MH, Alvarado, E, Pons, M, Magaz, M, Llop, E, Alvarez-Navascués, C, Navarrete, AA, Berenguer, M, Masnou, H, Bañares, R, Casado, M, Ampuero, J, Rios, J, Saavedra, C, Blasi, A, Lisman, T, Figuero, CR, Huelin, P, Tellez, L, Arráez, DM, Rodriguez, M, Aguilera, V, Loste, MTA, Baiges, A, Hernandez-Gea, V, Perelló, C, Calleja, JL, Genescà, J, Villanueva, C, Gonzalez-Alayón, C, Albillos, A, Crespo, J, Garcia-Pagán, JC. Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study. JOURNAL OF HEPATOLOGY. 2025; 83(5)DOI:10.1016/j.jhep.2025.06.035. PMID:40691992. IF:33.000(Q1/1D).
01/11/2025 Executive summary. Screening, staging and follow-up of type 1 diabetes in preclinical stages: Consensus of the scientific societies SED, SEEN and SEEP
Martinez-Brocca, MA, Bellido, V, Cardona-Hernandez, R, Castaño, L, Conget, I, Fernández, A, Gila, ALG, Leiva-Gea, I, Mauricio, D. Executive summary. Screening, staging and follow-up of type 1 diabetes in preclinical stages: Consensus of the scientific societies SED, SEEN and SEEP. Endocrinologia Diabetes y Nutricion. 2025; 72(9)DOI:10.1016/j.endinu.2025.501639. PMID:41111054. IF:1.800(Q3/8D).
01/11/2025 Oxytocin in hypopituitarism: What do we know?
Aulinas, A, Lawson, EA. Oxytocin in hypopituitarism: What do we know?. Endocrinologia Diabetes y Nutricion. 2025; 72(9)DOI:. PMID:41173566. IF:1.800(Q3/8D).
01/11/2025 Unraveling the gut-fat-inflammation connection in Crohn's disease: A path to new therapeutic targets?
Giordano, A, Bastón-Rey, I, Madero, L, Brunet-Mas, E, Calafat, M. Unraveling the gut-fat-inflammation connection in Crohn's disease: A path to new therapeutic targets?. Gastroenterologia y Hepatologia. 2025; 48(9)DOI:10.1016/j.gastrohep.2025.502466. PMID:40378950. IF:1.900(Q3/7D).
01/11/2025 Colonoscopy in symptomatic patients: Validation of AEG-SEED prioritization criteria and added value of FIT. The endoprior study
Rivero-Sánchez, L, Castillo-Iturra, J, Garcia-Rodriguez, A, Zafra, BG, Redondo, PD, Rodriguez, HN, Ponce, M, San Juan, M, Barrera, PB, Seoane, A, Carrasco, MA, Zaffalon, D, Guarner, C, Murzi, M, Jover, R, Medina-Prado, L, Rubio, KA, Matias, DJ, Suárez, BG, Córdova, H, Fernández-Simón, A, Araujo, I, Ginés, A, Pellisé, M, Balaguer, F, Fernández-Esparrach, G. Colonoscopy in symptomatic patients: Validation of AEG-SEED prioritization criteria and added value of FIT. The endoprior study. Gastroenterologia y Hepatologia. 2025; 48(9)DOI:10.1016/j.gastrohep.2025.502471. PMID:40409590. IF:1.900(Q3/7D).
01/11/2025 Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis (vol 83, pg 70, 2025)
Fortea, JI, Alvarado-Tapias, E, Simbrunner, B, Ezcurra, I, Hernández-Gea, V, Aracil, C, Llop, E, Puente, A, Roig, C, Reiberger, T, Garcia-Pagan, JC, Calleja, JL, Ferrero-Gregori, A, Mandorfer, M, Villanueva, C, Crespo, J. Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis (vol 83, pg 70, 2025). JOURNAL OF HEPATOLOGY. 2025; 83(5)DOI:10.1016/j.jhep.2025.08.004. PMID:40914642. IF:33.000(Q1/1D).
01/11/2025 Mapping MSU crystal deposition within MTP joints in tophaceous gout: a dual-energy CT study
De Silva, C, Díaz-Torné, C, Gamble, G, Horne, A, Doyle, A, Stamp, LK, Dalbeth, N. Mapping MSU crystal deposition within MTP joints in tophaceous gout: a dual-energy CT study. RHEUMATOLOGY. 2025; 64(11)DOI:10.1093/rheumatology/keaf347. PMID:40581776. IF:4.400(Q1/1D).
01/11/2025 Age-standardized comparison of coronary artery disease, stroke incidence, and all-cause mortality between people living with HIV and the general population in Spain
Camps-Vilaró, A, Teira, R, Subirana, I, Dégano, IR, Domingo, P, Curran, A, Montero-Alonso, M, Romero, A, Marrugat, J, Galindo, MJ. Age-standardized comparison of coronary artery disease, stroke incidence, and all-cause mortality between people living with HIV and the general population in Spain. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2025; 160DOI:10.1016/j.ijid.2025.108061. PMID:40953693. IF:4.300(Q1/2D).